| Literature DB >> 35406012 |
Alexey V Sokolov1,2, Nadezhda M Dubrovskaya3, Valeria A Kostevich1, Dmitrii S Vasilev3, Irina V Voynova1, Elena T Zakharova1, Olga L Runova1, Igor V Semak4, Alexander I Budevich5, Natalia N Nalivaeva3, Vadim B Vasilyev1,2.
Abstract
The protective effects of recombinant human lactoferrin rhLF (branded "CAPRABEL™") on the cognitive functions of rat offspring subjected to prenatal hypoxia (7% O2, 3 h, 14th day of gestation) have been analyzed. About 90% of rhLF in CAPRABEL was iron-free (apo-LF). Rat dams received several injections of 10 mg of CAPRABEL during either gestation (before and after the hypoxic attack) or lactation. Western blotting revealed the appearance of erythropoietin (EPO) alongside the hypoxia-inducible factors (HIFs) in organ homogenates of apo-rhLF-treated pregnant females, their embryos (but not placentas), and in suckling pups from the dams treated with apo-rhLF during lactation. Apo-rhLF injected to rat dams either during pregnancy or nurturing the pups was able to rescue cognitive deficits caused by prenatal hypoxia and improve various types of memory both in young and adult offspring when tested in the radial maze and by the Novel Object Recognition (NOR) test. The data obtained suggested that the apo-form of human LF injected to female rats during gestation or lactation protects the cognitive functions of their offspring impaired by prenatal hypoxia.Entities:
Keywords: cognitive functions; erythropoietin; hypoxia; hypoxia-inducible factor; lactoferrin; pregnancy
Mesh:
Substances:
Year: 2022 PMID: 35406012 PMCID: PMC9003537 DOI: 10.3390/nu14071399
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1The scheme of apo-rhLF administration to pregnant and lactating rats. Red lines—days of apo-rhLF administration to pregnant or lactating rats. Blue arrows mark the periods of collecting the material for Western blotting (E14 and P14).
Groups of experimental animals and the means of their analysis.
| Rat Groups (N) | Substance Injected | Biochemical Tests | Behavioral Tests |
|---|---|---|---|
| Control with saline | Saline (0.5 mL; E9, 11, 13, 15) | 2 females and 10 embryos (E14); WB-EPO | NOR (P22, |
| Hypoxia (E14) with saline | Saline (0.5 mL; E9, 11, 13, 15) | 2 females and 16 embryos (E14); WB-EPO | NOR (P22, |
| Hypoxia (E14) with apo-rhLF during gestation—Hyp+LF1 | Apo-rhLF (10 mg in 0.5 mL of saline; E9, E11, E13, E15) | 2 females and 12 embryos (E14); WB: EPO | NOR (P22, |
| Hypoxia (E14) with apo-rhLF during lactation—Hyp+LF2 | Apo-rhLF (10 mg in 0.5 mL of saline; daily from P0 to P15 days after birth) | 4 females and 16 pups (P14); WB: EPO, HIF1α and HIF2α | NOR (P22, |
| Control with apo-rhLF during lactation | Apo-rhLF (10 mg in 0.5 mL of saline; daily from P0 to P15 days after birth) | 3 females and 9 pups (P14); WB: EPO, HIF1α and HIF2α; | |
| Control with apo-rhLF during lactation | Apo-rhLF (single injection 10 mg in 0.5 mL of saline on P14) | 3 females and 6 pups (P14) WB: LF in dam milk and in the pup gastric content |
Figure 2Western blotting analysis with anti-EPO of brain homogenates from rat females and their embryos. 1 and 3: Brain samples of the embryos from rats subjected to hypoxia without injection of apo-rhLF; 4: brain sample of an intact pregnant rat injected with saline (no hypoxia); 5 and 6: brain samples of the embryos from rats injected with apo-rhLF during pregnancy; 7–10: brain samples of the embryos from rats injected with apo-rhLF; 2: molecular mass markers; arrow marks M 40 kDa. Hypoxia −/+ or apo-rhLF −/+ indicate whether hypoxia or apo-rhLF have been applied.
EPO detection by Western blotting in pregnant rats and their embryos.
| Groups | Analyzed Part of Pregnant Rats or Fetus | ||||
|---|---|---|---|---|---|
| Brain of Pregnant Females | Placenta | Brain of the Embryos | Torso of the Embryos | ||
| Embryos ( | EPO presence | 0 | 0 | 0 | 0 |
| EPO absence | 2 | 10 | 10 | 10 | |
| Embryos ( | EPO presence | 0 | 0 | 0 | 0 |
| EPO absence | 2 | 16 | 16 | 16 | |
| Embryos ( | EPO presence | 2 | 0 | 12 | 12 |
| EPO absence | 0 | 12 | 0 | 0 | |
Figure 3Western blotting with anti-LF antibody of lactating rat milk and of the gastric content of their pups. 1–3: Gastric content of pups (P14) fed by the rats injected with apo-rhLF; 4: control sample of CAPRABEL (1 µg); 5: molecular mass markers, arrows mark 70 and 50 kDa; 6–8: milk from rats injected with apo-rhLF; 9–10 milk from control rats injected with saline.
HIF-1α, HIF-2α and EPO detection by Western blotting in organs of pups.
| Organ | Pups ( | Pups ( | Pups ( | |||
|---|---|---|---|---|---|---|
| HIF1α HIF2α and EPO Presence | HIF1α HIF2α and EPO Absence | HIF1α HIF2α and EPO Presence | HIF1α HIF2α and EPO Absence | HIF1α HIF2α and EPO Presence | HIF1α HIF2α and EPO Absence | |
| Brain | 9 | 0 | 0 | 11 | 16 | 0 |
| Liver | 9 | 0 | 0 | 11 | 16 | 0 |
| Spleen | 9 | 0 | 0 | 11 | 16 | 0 |
Figure 4Results of testing short-term memory (STM) and long-term memory (LTM1 and LTM2) in the offspring of hypoxia-treated rats by Novel Object Recognition test. Ordinate: mean ± SEM of the time spent exploring novel objects expressed in % of the total time spent exploring both the novel and familiar objects. (A)—Rats tested on postnatal day 22; (B)—Rats tested on postnatal day 90. *—p ≤ 0.05; **—p ≤ 0.01; ***—p ≤ 0.01 (one sample test) differences between the time spent exploring the novel object and the hypothetical 50% value (the horizontal line) in case of equal preference for the novel and familiar objects. The number of animals in each group is specified in the Methods. Hyp—hypoxia; Hyp+LF1—hypoxia and apo-rhLF during gestation; Hyp+LF2—hypoxia and apo-rhLF during lactation.
Figure 5Effect of apo-rhLF on the working short-term memory of adult offspring (P90) tested in the two-level, eight-arm radial maze. Ordinate: number of erroneous runs in % (mean ± SEM). *—p ≤ 0.05; **—p ≤ 0.01—difference between Hyp and other groups (one-way ANOVA: F3,27 = 8.064, p = 0.001, Tukey–Kramer post hoc test). The number of animals in each group is specified in the Methods. Hyp—hypoxia; Hyp+LF1—hypoxia and apo-rhLF during gestation; Hyp+LF2—hypoxia and apo-rhLF during lactation.